Diagnostics firm Exagen's Q3 revenue slightly beats estimates on higher test volumes, prices
XGN•Exagen's third-quarter revenue rose 7% to $18.42 million, slightly above the $18.34 million analyst estimate, as test volumes and prices increased. The company reiterated its 2026 revenue guidance of $72 million to $75 million.
1. Revenue and losses
Exagen reported third-quarter revenue of $18.42 million, up 7% and slightly above the $18.34 million consensus estimate. Net loss was $6.34 million, down 12%, while adjusted EBITDA loss improved by more than 30%.
2. Outlook and drivers
The company reiterated full-year 2026 revenue guidance of $72 million to $75 million and said it remains on track to launch its myositis offering in early 2027. Average selling prices for AVISE CTD tests rose for the 14th consecutive quarter, and test volumes increased from a year earlier.
